B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up
Engineered B cell platform company Be Bio moves autologous therapies toward clinic, attracts Arch with allogeneic strategy
Although Be Bio isn’t yet disclosing any details of its nascent pipeline programs, the engineered B cell therapy developer intends to use its new $130 million series B round to beef up infrastructure and further refine its platform while continuing to build its team.
Arch Venture Partners led the round, in which new investor Bristol Myers Squibb Co. (NYSE:BMY) also participated alongside existing VCs. A syndicate led by Atlas Venture and RA Capital had backed Be Biopharma Inc. in October 2020 with a $52 million series A round...